Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Apr 14;106(7):e348–e349. doi: 10.1097/TP.0000000000004166

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

FIGURE 1. — Histopathological findings of liver allograft biopsies after SARS-CoV-2 mRNA vaccination (Pfizer-BioNTech) for case 1 (A, H&E ×400), case 2 (B, H&E ×100), and case 3 (C, H&E ×400; D, H&E ×400). A, Post vaccination biopsy for Case 1 showed moderate to severe T cell mediated rejection with all portal tracts infiltrated and expanded by activated lymphocytes, neutrophils and eosinophils. Endotheliitis (*) and lymphocytic bile duct injury (arrow) were present in most portal tracts. B, Post vaccination biopsy for Case 2 showed severe T cell mediated rejection with expansile portal infiltrates (*), marked cholestatic lobular injury (arrow) and central venule perivenulitis with hepatocyte drop-out (#).C and D, Case 3 showed typical rejection infiltrate with endotheliitis (arrows), lymphocytic cholangitis (*) and limited lymphocytic central perivenulitis with perivenular hepatocyte damage (#).